However, mesothelin is overexpressed in a high percentage of ovarian cancers, pancreatic cancers, non–small lung cancers, and mesotheliomas, making it a potential target for anti-cancer treatments [3–7]. Here, MSLN is linked to familial pancreatic carcinoma.